Literature DB >> 10027650

Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants.

M Ida1, S Kageyama, H Sato, T Kamiyama, J Yamamura, M Kurokawa, M Morohashi, K Shiraki.   

Abstract

We have characterized the differential actions of acyclovir and penciclovir against varicella-zoster virus (VZV) in cell culture by comparing the frequency of appearance of resistant viruses followed by their characterization. Cells were infected with cell-free virus and the cultures were successively treated with increasing concentrations of acyclovir or penciclovir. Drug-resistant viruses were selected in the presence of 6 microg/ml of acyclovir or penciclovir. The emergence frequency of resistant viruses was significantly higher following acyclovir exposure than following penciclovir exposure (Fisher's exact test, P<0.0001), possibly reflecting virus growth differences under these experimental conditions. Based on antiviral drug susceptibility and thymidine kinase (TK) activity assays, 11 acyclovir-resistant variants from seven experiments using three virus strains (Kawaguchi strain, Oka varicella vaccine strain and a clinical isolate from a zoster patient) were found to be TK-deficient. Sequence analysis of TK-deficient variants of the Kawaguchi strain revealed deletions that caused frameshifts, resulting in premature termination in the TK gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027650     DOI: 10.1016/s0166-3542(98)00057-6

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication.

Authors:  Robert J Visalli; Jeanette Fairhurst; Shamala Srinivas; William Hu; Boris Feld; Martin DiGrandi; Kevin Curran; Adma Ross; Jonathan D Bloom; Marja van Zeijl; Thomas R Jones; John O'Connell; Jeffrey I Cohen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.

Authors:  R T Sarisky; M R Quail; P E Clark; T T Nguyen; W S Halsey; R J Wittrock; J O'Leary Bartus; M M Van Horn; G M Sathe; S Van Horn; M D Kelly; T H Bacon; J J Leary
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.

Authors:  G Andrei; D Topalis; P Fiten; C McGuigan; J Balzarini; G Opdenakker; R Snoeck
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

Review 4.  Valaciclovir: a review of its use in the management of herpes zoster.

Authors:  D Ormrod; K Goa
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

5.  Identification of ribonucleotide reductase mutation causing temperature-sensitivity of herpes simplex virus isolates from whitlow by deep sequencing.

Authors:  Tohru Daikoku; Yukari Oyama; Misako Yajima; Tsuyoshi Sekizuka; Makoto Kuroda; Yuka Shimada; Kazuhiko Takehara; Naoko Miwa; Tomoko Okuda; Tetsutaro Sata; Kimiyasu Shiraki
Journal:  Clin Case Rep       Date:  2015-04-22

Review 6.  Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

Review 7.  Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.

Authors:  Kimiyasu Shiraki; Tohru Daikoku
Journal:  Pharmacol Ther       Date:  2020-02-22       Impact factor: 12.310

8.  Anti-varicella-zoster virus activity of cephalotaxine esters in vitro.

Authors:  Jung-Eun Kim; Yoon-Jae Song
Journal:  J Microbiol       Date:  2018-11-19       Impact factor: 3.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.